CUMBERLAND PHARMACEUTICALS INC
CPIXDrugs in Pipeline
22
Phase 3 Programs
8
Upcoming Catalysts
1
Next Catalyst
Jan 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How CPIX's past catalysts played out
Telavancin
Bacterial Pneumonia
YM087
Hyponatremia
conivaptan
Liver Cirrhosis
YM087 oral
Hyponatremia
Vancomycin
Bacterial Pneumonia
ibuprofen
Fever
Caldolor
Burns
Intravenous ibuprofen
Pain
Ifetroban, Oral Capsule
Aspirin Exacerbated Respiratory Disease (AERD)
Full dose preparation
Colonoscopy Preparation
N-Acetylcysteine (NAC)
Radiocontrast Nephropathy
ranibizumab
Retinal Vein Occlusion
Crystalline Lactulose
Colonoscopy
Vancomycin or antistaphylococcal penicillin
Infections, Gram-Positive Bacterial
Vancomycin, nafcillin, oxacillin, or cloxacillin
Gram-Positive Bacterial Infections
Ifetroban
Duchenne Muscular Dystrophy Cardiomyopathy
Ifetroban Injection
Hepatorenal Syndrome
Ifetroban Sodium
Idiopathic Pulmonary Fibrosis
Ifetroban Oral Capsule
Asthma, Aspirin-Induced
Atorvastatin injection
Hypercholesterolemia
Oral Ifetroban
Scleroderma, Diffuse
90 grams of Crystalline Lactulose
Colonoscopy Preparation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Telavancin | Phase 3 | Bacterial Pneumonia | - | - |
YM087 | Phase 3 | Hyponatremia | - | - |
conivaptan | Phase 3 | Liver Cirrhosis | - | - |
YM087 oral | Phase 3 | Hyponatremia | - | - |
Vancomycin | Phase 3 | Bacterial Pneumonia | - | - |
ibuprofen | Phase 3 | Fever | - | - |
Caldolor | Phase 3 | Burns | - | - |
Intravenous ibuprofen | Phase 3 | Pain | - | - |
Ifetroban, Oral Capsule | Phase 2 | Aspirin Exacerbated Respiratory Disease (AERD) | - | - |
Full dose preparation | Phase 2 | Colonoscopy Preparation | - | - |
N-Acetylcysteine (NAC) | Phase 2 | Radiocontrast Nephropathy | - | - |
ranibizumab | Phase 2 | Retinal Vein Occlusion | - | - |
Crystalline Lactulose | Phase 2 | Colonoscopy | - | - |
Vancomycin or antistaphylococcal penicillin | Phase 2 | Infections, Gram-Positive Bacterial | - | - |
Vancomycin, nafcillin, oxacillin, or cloxacillin | Phase 2 | Gram-Positive Bacterial Infections | - | - |
Ifetroban | Phase 2 | Duchenne Muscular Dystrophy Cardiomyopathy | - | - |
Ifetroban Injection | Phase 2 | Hepatorenal Syndrome | - | - |
Ifetroban Sodium | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Ifetroban Oral Capsule | Phase 2 | Asthma, Aspirin-Induced | - | - |
Atorvastatin injection | Phase 2 | Hypercholesterolemia | - | - |
Oral Ifetroban | Phase 2 | Scleroderma, Diffuse | - | - |
90 grams of Crystalline Lactulose | Phase 2 | Colonoscopy Preparation | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CUMBERLAND PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 22 drug candidates in CUMBERLAND PHARMACEUTICALS INC's (CPIX) pipeline across Phase 3, Phase 2. Its lead program is Telavancin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CUMBERLAND PHARMACEUTICALS INC's next FDA catalyst?→
CUMBERLAND PHARMACEUTICALS INC's (CPIX) next tracked catalyst is a Phase 2 expected January 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CPIX biotech catalysts?→
Add CPIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CUMBERLAND PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.